산후 우울증 치료제 시장 규모, 점유율, 동향 분석 : 치료별, 투여 경로별, 유통 채널별, 유형별, 지역별, 전망 및 예측(2024-2031년)

The Global Postpartum Depression Drugs Market size is expected to reach $1.7 billion by 2031, rising at a market growth of 9.4% CAGR during the forecast period.

There is growing awareness among healthcare professionals and the public in the Asia-Pacific region regarding postpartum depression (PPD) and its impact on maternal mental health. Improved recognition of PPD symptoms leads to more women seeking diagnosis and treatment, thereby driving up demand for pharmacotherapy. Consequently, the Asia pacific region would acquire nearly 28% of the total market share by 2031.

Neuroendocrinology explores the interactions between the nervous system and endocrine system, which is crucial during the postpartum period. A deeper understanding of neuroendocrine changes allows for earlier identification of potential problems. Thus, rising focus on neuroendocrinology is driving the growth of the market.

Additionally, Awareness campaigns educate healthcare providers and new mothers about the symptoms and risks of postpartum depression (PPD). Furthermore, awareness initiatives often include training healthcare professionals to recognize signs of PPD during routine postnatal care visits. Thus, increasing awareness and screening programs are driving the market's growth.

However, Many PPD drugs, particularly antidepressants, can cause side effects such as nausea, fatigue, dizziness, insomnia, and weight gain. In addition, for newer PPD drugs, there may be limited long-term safety data available. This uncertainty can make healthcare providers and patients cautious about using these medications until more comprehensive data is available. Hence, side effects and safety concerns of the drug are hindering the growth of the market.

Moreover, Clinical trials for new these drugs were halted or delayed due to pandemic-related restrictions. This slowed the development and approval process of innovative therapies that could have benefited patients. Economic uncertainties during the pandemic affected patients' ability to afford medications and healthcare services. This financial strain further limited access to these drugs, especially in regions with inadequate healthcare coverage. The isolation and stress caused by the pandemic exacerbated mental health conditions, including postpartum depression. This increased demand for treatment but posed challenges in delivering effective care and support remotely. Thus, the COVID-19 pandemic had a negative impact on the market.

Treatment Outlook

On the basis of treatment, the market is segmented into pharmacotherapy, hormonal therapy, and others. In 2023, the hormonal therapy segment attained 29% revenue share in the market. After childbirth, women experience significant hormonal fluctuations, including drops in estrogen and progesterone levels.

Route of Administration Outlook

By route of administration, the market is divided into parenteral, oral, and others. The parenteral segment procured 24% revenue share in the market in 2023. Parenteral medications typically have a faster onset of action compared to oral medications. This rapid response is beneficial for women experiencing severe or acute symptoms of postpartum depression (PPD), providing quicker relief and stabilization of mood.

Distribution Channel Outlook

The market is categorized by distribution channel into hospital pharmacies, retail pharmacy, and others. The retail pharmacy segment witnessed 35% revenue share in the market in 2023. Pharmacists in retail settings are increasingly trained to identify symptoms of PPD and collaborate with healthcare providers to facilitate appropriate medication management.

Type Outlook

Based on type, the market is divided into postpartum blues, postpartum anxiety, postpartum obsessive-compulsive disorder (OCD), postpartum post-traumatic stress disorder (PTSD), postpartum panic disorder, and postpartum psychosis. The postpartum blues segment attained 25% revenue share in the market in 2023. Postpartum blues, also known as baby blues, are common and transient mood changes experienced by many new mothers within the first few weeks after childbirth.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 39% revenue share in the market in 2023. Access to healthcare services, including mental health professionals and pharmacotherapy, is generally better in North America than in many other regions. This accessibility facilitates timely diagnosis and treatment initiation for women experiencing PPD symptoms. The pharmaceutical industry in North America is well-developed, with a wide range of medications approved for treating PPD.

List of Key Companies Profiled

• Pfizer, Inc.
• Eli Lilly And Company
• Novartis AG
• GlaxoSmithKline PLC (GSK)
• Merck & Co., Inc.
• Biogen, Inc.
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies, Inc.(DermTech, Inc.)
• Cipla Limited
• Sage Therapeutics, Inc.

Global Postpartum Depression Drugs Market Report Segmentation

By Treatment

• Pharmacotherapy
• Hormonal Therapy
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Type

• Postpartum Anxiety
• Postpartum Blues
• Postpartum Obsessive-Compulsive Disorder (OCD)
• Postpartum Panic Disorder
• Postpartum Post-Traumatic Stress Disorder (PTSD)
• Postpartum Psychosis

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Postpartum Depression Drugs Market, by Treatment
  • 1.4.2 Global Postpartum Depression Drugs Market, by Route of Administration
  • 1.4.3 Global Postpartum Depression Drugs Market, by Distribution Channel
  • 1.4.4 Global Postpartum Depression Drugs Market, by Type
  • 1.4.5 Global Postpartum Depression Drugs Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges
• 3.3 Porter Five Forces Analysis

Chapter 4. Global Postpartum Depression Drugs Market by Treatment

• 4.1 Global Pharmacotherapy Market by Region
• 4.2 Global Hormonal Therapy Market by Region
• 4.3 Global Others Market by Region

Chapter 5. Global Postpartum Depression Drugs Market by Route of Administration

• 5.1 Global Oral Market by Region
• 5.2 Global Parenteral Market by Region
• 5.3 Global Others Market by Region

Chapter 6. Global Postpartum Depression Drugs Market by Distribution Channel

• 6.1 Global Hospital Pharmacy Market by Region
• 6.2 Global Retail Pharmacy Market by Region
• 6.3 Global Online Pharmacy Market by Region

Chapter 7. Global Postpartum Depression Drugs Market by Type

• 7.1 Global Postpartum Anxiety Market by Region
• 7.2 Global Postpartum Blues Market by Region
• 7.3 Global Postpartum Obsessive-Compulsive Disorder (OCD) Market by Region
• 7.4 Global Postpartum Panic Disorder Market by Region
• 7.5 Global Postpartum Post-Traumatic Stress Disorder (PTSD) Market by Region
• 7.6 Global Postpartum Psychosis Market by Region

Chapter 8. Global Postpartum Depression Drugs Market by Region

• 8.1 North America Postpartum Depression Drugs Market
  • 8.1.1 North America Postpartum Depression Drugs Market by Treatment
    • 8.1.1.1 North America Pharmacotherapy Market by Country
    • 8.1.1.2 North America Hormonal Therapy Market by Country
    • 8.1.1.3 North America Others Market by Country
  • 8.1.2 North America Postpartum Depression Drugs Market by Route of Administration
    • 8.1.2.1 North America Oral Market by Country
    • 8.1.2.2 North America Parenteral Market by Country
    • 8.1.2.3 North America Others Market by Country
  • 8.1.3 North America Postpartum Depression Drugs Market by Distribution Channel
    • 8.1.3.1 North America Hospital Pharmacy Market by Country
    • 8.1.3.2 North America Retail Pharmacy Market by Country
    • 8.1.3.3 North America Online Pharmacy Market by Country
  • 8.1.4 North America Postpartum Depression Drugs Market by Type
    • 8.1.4.1 North America Postpartum Anxiety Market by Country
    • 8.1.4.2 North America Postpartum Blues Market by Country
    • 8.1.4.3 North America Postpartum Obsessive-Compulsive Disorder (OCD) Market by Country
    • 8.1.4.4 North America Postpartum Panic Disorder Market by Country
    • 8.1.4.5 North America Postpartum Post-Traumatic Stress Disorder (PTSD) Market by Country
    • 8.1.4.6 North America Postpartum Psychosis Market by Country
  • 8.1.5 North America Postpartum Depression Drugs Market by Country
    • 8.1.5.1 US Postpartum Depression Drugs Market
      • 8.1.5.1.1 US Postpartum Depression Drugs Market by Treatment
      • 8.1.5.1.2 US Postpartum Depression Drugs Market by Route of Administration
      • 8.1.5.1.3 US Postpartum Depression Drugs Market by Distribution Channel
      • 8.1.5.1.4 US Postpartum Depression Drugs Market by Type
    • 8.1.5.2 Canada Postpartum Depression Drugs Market
      • 8.1.5.2.1 Canada Postpartum Depression Drugs Market by Treatment
      • 8.1.5.2.2 Canada Postpartum Depression Drugs Market by Route of Administration
      • 8.1.5.2.3 Canada Postpartum Depression Drugs Market by Distribution Channel
      • 8.1.5.2.4 Canada Postpartum Depression Drugs Market by Type
    • 8.1.5.3 Mexico Postpartum Depression Drugs Market
      • 8.1.5.3.1 Mexico Postpartum Depression Drugs Market by Treatment
      • 8.1.5.3.2 Mexico Postpartum Depression Drugs Market by Route of Administration
      • 8.1.5.3.3 Mexico Postpartum Depression Drugs Market by Distribution Channel
      • 8.1.5.3.4 Mexico Postpartum Depression Drugs Market by Type
    • 8.1.5.4 Rest of North America Postpartum Depression Drugs Market
      • 8.1.5.4.1 Rest of North America Postpartum Depression Drugs Market by Treatment
      • 8.1.5.4.2 Rest of North America Postpartum Depression Drugs Market by Route of Administration
      • 8.1.5.4.3 Rest of North America Postpartum Depression Drugs Market by Distribution Channel
      • 8.1.5.4.4 Rest of North America Postpartum Depression Drugs Market by Type
• 8.2 Europe Postpartum Depression Drugs Market
  • 8.2.1 Europe Postpartum Depression Drugs Market by Treatment
    • 8.2.1.1 Europe Pharmacotherapy Market by Country
    • 8.2.1.2 Europe Hormonal Therapy Market by Country
    • 8.2.1.3 Europe Others Market by Country
  • 8.2.2 Europe Postpartum Depression Drugs Market by Route of Administration
    • 8.2.2.1 Europe Oral Market by Country
    • 8.2.2.2 Europe Parenteral Market by Country
    • 8.2.2.3 Europe Others Market by Country
  • 8.2.3 Europe Postpartum Depression Drugs Market by Distribution Channel
    • 8.2.3.1 Europe Hospital Pharmacy Market by Country
    • 8.2.3.2 Europe Retail Pharmacy Market by Country
    • 8.2.3.3 Europe Online Pharmacy Market by Country
  • 8.2.4 Europe Postpartum Depression Drugs Market by Type
    • 8.2.4.1 Europe Postpartum Anxiety Market by Country
    • 8.2.4.2 Europe Postpartum Blues Market by Country
    • 8.2.4.3 Europe Postpartum Obsessive-Compulsive Disorder (OCD) Market by Country
    • 8.2.4.4 Europe Postpartum Panic Disorder Market by Country
    • 8.2.4.5 Europe Postpartum Post-Traumatic Stress Disorder (PTSD) Market by Country
    • 8.2.4.6 Europe Postpartum Psychosis Market by Country
  • 8.2.5 Europe Postpartum Depression Drugs Market by Country
    • 8.2.5.1 Germany Postpartum Depression Drugs Market
      • 8.2.5.1.1 Germany Postpartum Depression Drugs Market by Treatment
      • 8.2.5.1.2 Germany Postpartum Depression Drugs Market by Route of Administration
      • 8.2.5.1.3 Germany Postpartum Depression Drugs Market by Distribution Channel
      • 8.2.5.1.4 Germany Postpartum Depression Drugs Market by Type
    • 8.2.5.2 UK Postpartum Depression Drugs Market
      • 8.2.5.2.1 UK Postpartum Depression Drugs Market by Treatment
      • 8.2.5.2.2 UK Postpartum Depression Drugs Market by Route of Administration
      • 8.2.5.2.3 UK Postpartum Depression Drugs Market by Distribution Channel
      • 8.2.5.2.4 UK Postpartum Depression Drugs Market by Type
    • 8.2.5.3 France Postpartum Depression Drugs Market
      • 8.2.5.3.1 France Postpartum Depression Drugs Market by Treatment
      • 8.2.5.3.2 France Postpartum Depression Drugs Market by Route of Administration
      • 8.2.5.3.3 France Postpartum Depression Drugs Market by Distribution Channel
      • 8.2.5.3.4 France Postpartum Depression Drugs Market by Type
    • 8.2.5.4 Russia Postpartum Depression Drugs Market
      • 8.2.5.4.1 Russia Postpartum Depression Drugs Market by Treatment
      • 8.2.5.4.2 Russia Postpartum Depression Drugs Market by Route of Administration
      • 8.2.5.4.3 Russia Postpartum Depression Drugs Market by Distribution Channel
      • 8.2.5.4.4 Russia Postpartum Depression Drugs Market by Type
    • 8.2.5.5 Spain Postpartum Depression Drugs Market
      • 8.2.5.5.1 Spain Postpartum Depression Drugs Market by Treatment
      • 8.2.5.5.2 Spain Postpartum Depression Drugs Market by Route of Administration
      • 8.2.5.5.3 Spain Postpartum Depression Drugs Market by Distribution Channel
      • 8.2.5.5.4 Spain Postpartum Depression Drugs Market by Type
    • 8.2.5.6 Italy Postpartum Depression Drugs Market
      • 8.2.5.6.1 Italy Postpartum Depression Drugs Market by Treatment
      • 8.2.5.6.2 Italy Postpartum Depression Drugs Market by Route of Administration
      • 8.2.5.6.3 Italy Postpartum Depression Drugs Market by Distribution Channel
      • 8.2.5.6.4 Italy Postpartum Depression Drugs Market by Type
    • 8.2.5.7 Rest of Europe Postpartum Depression Drugs Market
      • 8.2.5.7.1 Rest of Europe Postpartum Depression Drugs Market by Treatment
      • 8.2.5.7.2 Rest of Europe Postpartum Depression Drugs Market by Route of Administration
      • 8.2.5.7.3 Rest of Europe Postpartum Depression Drugs Market by Distribution Channel
      • 8.2.5.7.4 Rest of Europe Postpartum Depression Drugs Market by Type
• 8.3 Asia Pacific Postpartum Depression Drugs Market
  • 8.3.1 Asia Pacific Postpartum Depression Drugs Market by Treatment
    • 8.3.1.1 Asia Pacific Pharmacotherapy Market by Country
    • 8.3.1.2 Asia Pacific Hormonal Therapy Market by Country
    • 8.3.1.3 Asia Pacific Others Market by Country
  • 8.3.2 Asia Pacific Postpartum Depression Drugs Market by Route of Administration
    • 8.3.2.1 Asia Pacific Oral Market by Country
    • 8.3.2.2 Asia Pacific Parenteral Market by Country
    • 8.3.2.3 Asia Pacific Others Market by Country
  • 8.3.3 Asia Pacific Postpartum Depression Drugs Market by Distribution Channel
    • 8.3.3.1 Asia Pacific Hospital Pharmacy Market by Country
    • 8.3.3.2 Asia Pacific Retail Pharmacy Market by Country
    • 8.3.3.3 Asia Pacific Online Pharmacy Market by Country
  • 8.3.4 Asia Pacific Postpartum Depression Drugs Market by Type
    • 8.3.4.1 Asia Pacific Postpartum Anxiety Market by Country
    • 8.3.4.2 Asia Pacific Postpartum Blues Market by Country
    • 8.3.4.3 Asia Pacific Postpartum Obsessive-Compulsive Disorder (OCD) Market by Country
    • 8.3.4.4 Asia Pacific Postpartum Panic Disorder Market by Country
    • 8.3.4.5 Asia Pacific Postpartum Post-Traumatic Stress Disorder (PTSD) Market by Country
    • 8.3.4.6 Asia Pacific Postpartum Psychosis Market by Country
  • 8.3.5 Asia Pacific Postpartum Depression Drugs Market by Country
    • 8.3.5.1 China Postpartum Depression Drugs Market
      • 8.3.5.1.1 China Postpartum Depression Drugs Market by Treatment
      • 8.3.5.1.2 China Postpartum Depression Drugs Market by Route of Administration
      • 8.3.5.1.3 China Postpartum Depression Drugs Market by Distribution Channel
      • 8.3.5.1.4 China Postpartum Depression Drugs Market by Type
    • 8.3.5.2 Japan Postpartum Depression Drugs Market
      • 8.3.5.2.1 Japan Postpartum Depression Drugs Market by Treatment
      • 8.3.5.2.2 Japan Postpartum Depression Drugs Market by Route of Administration
      • 8.3.5.2.3 Japan Postpartum Depression Drugs Market by Distribution Channel
      • 8.3.5.2.4 Japan Postpartum Depression Drugs Market by Type
    • 8.3.5.3 India Postpartum Depression Drugs Market
      • 8.3.5.3.1 India Postpartum Depression Drugs Market by Treatment
      • 8.3.5.3.2 India Postpartum Depression Drugs Market by Route of Administration
      • 8.3.5.3.3 India Postpartum Depression Drugs Market by Distribution Channel
      • 8.3.5.3.4 India Postpartum Depression Drugs Market by Type
    • 8.3.5.4 South Korea Postpartum Depression Drugs Market
      • 8.3.5.4.1 South Korea Postpartum Depression Drugs Market by Treatment
      • 8.3.5.4.2 South Korea Postpartum Depression Drugs Market by Route of Administration
      • 8.3.5.4.3 South Korea Postpartum Depression Drugs Market by Distribution Channel
      • 8.3.5.4.4 South Korea Postpartum Depression Drugs Market by Type
    • 8.3.5.5 Singapore Postpartum Depression Drugs Market
      • 8.3.5.5.1 Singapore Postpartum Depression Drugs Market by Treatment
      • 8.3.5.5.2 Singapore Postpartum Depression Drugs Market by Route of Administration
      • 8.3.5.5.3 Singapore Postpartum Depression Drugs Market by Distribution Channel
      • 8.3.5.5.4 Singapore Postpartum Depression Drugs Market by Type
    • 8.3.5.6 Malaysia Postpartum Depression Drugs Market
      • 8.3.5.6.1 Malaysia Postpartum Depression Drugs Market by Treatment
      • 8.3.5.6.2 Malaysia Postpartum Depression Drugs Market by Route of Administration
      • 8.3.5.6.3 Malaysia Postpartum Depression Drugs Market by Distribution Channel
      • 8.3.5.6.4 Malaysia Postpartum Depression Drugs Market by Type
    • 8.3.5.7 Rest of Asia Pacific Postpartum Depression Drugs Market
      • 8.3.5.7.1 Rest of Asia Pacific Postpartum Depression Drugs Market by Treatment
      • 8.3.5.7.2 Rest of Asia Pacific Postpartum Depression Drugs Market by Route of Administration
      • 8.3.5.7.3 Rest of Asia Pacific Postpartum Depression Drugs Market by Distribution Channel
      • 8.3.5.7.4 Rest of Asia Pacific Postpartum Depression Drugs Market by Type
• 8.4 LAMEA Postpartum Depression Drugs Market
  • 8.4.1 LAMEA Postpartum Depression Drugs Market by Treatment
    • 8.4.1.1 LAMEA Pharmacotherapy Market by Country
    • 8.4.1.2 LAMEA Hormonal Therapy Market by Country
    • 8.4.1.3 LAMEA Others Market by Country
  • 8.4.2 LAMEA Postpartum Depression Drugs Market by Route of Administration
    • 8.4.2.1 LAMEA Oral Market by Country
    • 8.4.2.2 LAMEA Parenteral Market by Country
    • 8.4.2.3 LAMEA Others Market by Country
  • 8.4.3 LAMEA Postpartum Depression Drugs Market by Distribution Channel
    • 8.4.3.1 LAMEA Hospital Pharmacy Market by Country
    • 8.4.3.2 LAMEA Retail Pharmacy Market by Country
    • 8.4.3.3 LAMEA Online Pharmacy Market by Country
  • 8.4.4 LAMEA Postpartum Depression Drugs Market by Type
    • 8.4.4.1 LAMEA Postpartum Anxiety Market by Country
    • 8.4.4.2 LAMEA Postpartum Blues Market by Country
    • 8.4.4.3 LAMEA Postpartum Obsessive-Compulsive Disorder (OCD) Market by Country
    • 8.4.4.4 LAMEA Postpartum Panic Disorder Market by Country
    • 8.4.4.5 LAMEA Postpartum Post-Traumatic Stress Disorder (PTSD) Market by Country
    • 8.4.4.6 LAMEA Postpartum Psychosis Market by Country
  • 8.4.5 LAMEA Postpartum Depression Drugs Market by Country
    • 8.4.5.1 Brazil Postpartum Depression Drugs Market
      • 8.4.5.1.1 Brazil Postpartum Depression Drugs Market by Treatment
      • 8.4.5.1.2 Brazil Postpartum Depression Drugs Market by Route of Administration
      • 8.4.5.1.3 Brazil Postpartum Depression Drugs Market by Distribution Channel
      • 8.4.5.1.4 Brazil Postpartum Depression Drugs Market by Type
    • 8.4.5.2 Argentina Postpartum Depression Drugs Market
      • 8.4.5.2.1 Argentina Postpartum Depression Drugs Market by Treatment
      • 8.4.5.2.2 Argentina Postpartum Depression Drugs Market by Route of Administration
      • 8.4.5.2.3 Argentina Postpartum Depression Drugs Market by Distribution Channel
      • 8.4.5.2.4 Argentina Postpartum Depression Drugs Market by Type
    • 8.4.5.3 UAE Postpartum Depression Drugs Market
      • 8.4.5.3.1 UAE Postpartum Depression Drugs Market by Treatment
      • 8.4.5.3.2 UAE Postpartum Depression Drugs Market by Route of Administration
      • 8.4.5.3.3 UAE Postpartum Depression Drugs Market by Distribution Channel
      • 8.4.5.3.4 UAE Postpartum Depression Drugs Market by Type
    • 8.4.5.4 Saudi Arabia Postpartum Depression Drugs Market
      • 8.4.5.4.1 Saudi Arabia Postpartum Depression Drugs Market by Treatment
      • 8.4.5.4.2 Saudi Arabia Postpartum Depression Drugs Market by Route of Administration
      • 8.4.5.4.3 Saudi Arabia Postpartum Depression Drugs Market by Distribution Channel
      • 8.4.5.4.4 Saudi Arabia Postpartum Depression Drugs Market by Type
    • 8.4.5.5 South Africa Postpartum Depression Drugs Market
      • 8.4.5.5.1 South Africa Postpartum Depression Drugs Market by Treatment
      • 8.4.5.5.2 South Africa Postpartum Depression Drugs Market by Route of Administration
      • 8.4.5.5.3 South Africa Postpartum Depression Drugs Market by Distribution Channel
      • 8.4.5.5.4 South Africa Postpartum Depression Drugs Market by Type
    • 8.4.5.6 Nigeria Postpartum Depression Drugs Market
      • 8.4.5.6.1 Nigeria Postpartum Depression Drugs Market by Treatment
      • 8.4.5.6.2 Nigeria Postpartum Depression Drugs Market by Route of Administration
      • 8.4.5.6.3 Nigeria Postpartum Depression Drugs Market by Distribution Channel
      • 8.4.5.6.4 Nigeria Postpartum Depression Drugs Market by Type
    • 8.4.5.7 Rest of LAMEA Postpartum Depression Drugs Market
      • 8.4.5.7.1 Rest of LAMEA Postpartum Depression Drugs Market by Treatment
      • 8.4.5.7.2 Rest of LAMEA Postpartum Depression Drugs Market by Route of Administration
      • 8.4.5.7.3 Rest of LAMEA Postpartum Depression Drugs Market by Distribution Channel
      • 8.4.5.7.4 Rest of LAMEA Postpartum Depression Drugs Market by Type

Chapter 9. Company Profiles

• 9.1 Pfizer, Inc.
  • 9.1.1 Company Overview
  • 9.1.2 Financial Analysis
  • 9.1.3 Regional & Segmental Analysis
  • 9.1.4 Research & Development Expense
  • 9.1.5 SWOT Analysis
• 9.2 Eli Lilly And Company
  • 9.2.1 Company Overview
  • 9.2.2 Financial Analysis
  • 9.2.3 Regional Analysis
  • 9.2.4 Research & Development Expenses
  • 9.2.5 SWOT Analysis
• 9.3 Novartis AG
  • 9.3.1 Company Overview
  • 9.3.2 Financial Analysis
  • 9.3.3 Segmental and Regional Analysis
  • 9.3.4 Research & Development Expense
  • 9.3.5 SWOT Analysis
• 9.4 GlaxoSmithKline PLC (GSK)
  • 9.4.1 Company Overview
  • 9.4.2 Financial Analysis
  • 9.4.3 Regional Analysis
  • 9.4.4 Research & Development Expense
  • 9.4.5 SWOT Analysis
• 9.5 Merck & Co., Inc.
  • 9.5.1 Company Overview
  • 9.5.2 Financial Analysis
  • 9.5.3 Segmental and Regional Analysis
  • 9.5.4 Research & Development Expenses
  • 9.5.5 SWOT Analysis
• 9.6 Biogen, Inc.
  • 9.6.1 Company Overview
  • 9.6.2 Financial Analysis
  • 9.6.3 Regional Analysis
  • 9.6.4 Research & Development Expense
  • 9.6.5 Recent strategies and developments:
    • 9.6.5.1 Trails and Approvals:
  • 9.6.6 SWOT Analysis
• 9.7 Teva Pharmaceutical Industries Ltd.
  • 9.7.1 Company Overview
  • 9.7.2 Financial Analysis
  • 9.7.3 Regional Analysis
  • 9.7.4 Research & Development Expenses
  • 9.7.5 SWOT Analysis
• 9.8 Bausch Health Companies, Inc. (DermTech, Inc.)
  • 9.8.1 Company Overview
  • 9.8.2 Financial Analysis
  • 9.8.3 Segmental and Regional Analysis
  • 9.8.4 Research & Development Expense
  • 9.8.5 SWOT Analysis
• 9.9 Cipla Limited
  • 9.9.1 Company Overview
  • 9.9.2 Financial Analysis
  • 9.9.3 Segmental and Regional Analysis
  • 9.9.4 Research & Development Expense
  • 9.9.5 SWOT Analysis
• 9.10. Sage Therapeutics, Inc.
  • 9.10.1 Company Overview
  • 9.10.2 Financial Analysis
  • 9.10.3 Research & Development Expenses

Chapter 10. Winning Imperatives of Postpartum Depression Drugs Market